Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751792 | 0.86 | LMNA (0.49) | SMN1; SMN2LMNAUGCGTSHR | |
| SCHEMBL5755551 | 0.86 | LMNA (0.49) | SMN1; SMN2LMNAUGCGTSHR | |
| SCHEMBL5751263 | 0.83 | LMNA (0.46) | LMNAUGCGTSHR | |
| SCHEMBL5753673 | 0.82 | FFAR2 (0.52) | LMNAUGCGTSHR | |
| SCHEMBL5752050 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAPOLBHPGDTRPV1 | |
| SCHEMBL5751577 | 0.82 | RAB9A (0.39) | SMN1; SMN2LMNATRPV1RAB9ANPC1 | |
| SCHEMBL5753708 | 0.82 | NOS3 (0.43) | SMN1; SMN2LMNAUGCGHTT | |
| SCHEMBL5752870 | 0.81 | CYP1A2 (0.48) | SMN1; SMN2LMNARAB9ANPC1MAPT | |
| SCHEMBL5751360 | 0.78 | NOS3 (0.42) | SMN1; SMN2LMNAUGCGHTT | |
| SCHEMBL5752879 | 0.78 | LMNA (0.56) | SMN1; SMN2LMNAHPGDTRPV1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | SMN1; SMN2 4771/4885LMNA 2989/4885POLB 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.